ORGANOIDSCIENCES

ORGANOISCIENCES is a pioneering biotech company at the clinical stage, specializing in the development of cutting-edge, organoid-based therapeutics. These organoids are essentially miniaturized versions of organs created in vitro, showcasing true-to-life micro-anatomy. This technology is promising in the fields of regenerative medicine, precision medicine, and the discovery of new drugs. The company's platform, ATORM (Adult Tissue-derived Organoid-based Regenerative Medicine), leverages autologous, adult tissue-specific stem cells to address inflammatory bowel diseases. This innovative approach involves regenerating tissues by transplanting organoids directly onto damaged areas for fundamental treatment. With the U.S. FDA's recent shift away from animal testing, organoids have emerged as an ideal in vitro tool for drug discovery. Tumor organoid can mimic the unique characteristics and heterogeneity of individual patients.' ODISEI (Organoid-based Discovery platform for Innovative Screening, Evaluation, and Identification) platform is at the forefront of oncology drug discovery. It is a highly customizable platform capable of replicating the tumor microenvironment by co-culturing various cell types, including immune cells and cancer-associated fibroblasts. This setup is crucial in reproducing the tumor milieu, allowing researchers to analyze and unlock the therapeutic potential of patient-specific immune checkpoint inhibitors and they are now expanding to Precision Medicine.